Transplant-based treatments for the patient with long-standing type 1 diabetes

Diabetes: Translating Research into Practice

Volumn , Issue , 2008, Pages 193-208

  Khan, Mahfuzul ^a   Harlan, David M ^b,c  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 68149113968     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (48)

1. Achenbach P, Bonifacio E, Ziegler AG. Predicting type 1 diabetes. Curr Diab Rep 2005; 5(2):98–103.
2. Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39(7):857– 864.
3. Sutherland DE, Sibley R, Xu XZ, et al. Twin-to-twin pancreas transplantation: Reversal and reenactment of the pathogenesis of type I diabetes. Trans Assoc Am Physicians 1984; 97:80–87.
4. Heit JJ, Apelqvist AA, Gu X, et al. Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function. Nature 2006; 443(7109):345–349.
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329(14): 977–986.
6. Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353(25):2643– 2653.
7. Pambianco G, Costacou T, Ellis D, Becker DJ, Klein R, Orchard TJ. The 30-year natural history of type 1 diabetes complications: The Pittsburgh Epidemiology of Diabetes Complications Study experience. Diabetes 2006; 55(5):1463–1469.
8. Hovind P, Tarnow L, Rossing K, et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003; 26(4):1258–1264.
9. Nordwall M, Bojestig M, Arnqvist HJ, Ludvigsson J. Declining incidence of severe retinopathy and persisting decrease of nephropathy in an unselected population of Type 1 diabetes-the Linkoping Diabetes Complications Study. Diabetologia 2004; 47(7):1266–1272.
10. Finne P, Reunanen A, Stenman S, Groop PH, Gronhagen-Riska C. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294(14):1782–1787.
11. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Pancreas transplantation decreases survival for patients with diabetes and preserved kidney function. JAMA 2003; 290(21):2817–2823.
12. Liu EH, Siegel RM, Harlan DM, O’Shea JJ. T cell-directed therapies: Lessons learned and future prospects. Nat Immunol 2007; 8(1):25–30.
13. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation [see comments]. N Engl J Med 1998; 339(2):69–75.
14. Luzi L. Pancreas transplantation and diabetic complications. N Engl J Med 1998; 339(2):115–117.
15. Ramsay RC, Goetz FC, Sutherland DE, et al. Progression of diabetic retinopathy after pancreas transplantation for insulin-dependent diabetes mellitus. N Engl J Med 1988; 318(4):208–214.
16. Pearce IA, Ilango B, Sells RA, Wong D. Stabilisation of diabetic retinopathy following simultaneous pancreas and kidney transplant. Br J Ophthalmol 2000; 84(7):736– 740.
17. Chow VC, Pai RP, Chapman JR, et al. Diabetic retinopathy after combined kidney-pancreas transplantation. Clin Transplant 1999; 13(4):356–362.
18. Fioretto P, Mauer SM, Bilous RW, Goetz FC, Sutherland DE, Steffes MW. Effects of pancreas transplantation on glomerular structure in insulin-dependent diabetic patients with their own kidneys. Lancet 1993; 342(8881):1193–1196.
19. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341(23):1725–1730.
20. Bunnapradist S, Cho YW, Cecka JM, Wilkinson A, Danovitch GM. Kidney allograft and patient survival in type i diabetic recipients of cadaveric kidney alone versus simultaneous pancreas/kidney transplants: A multivariate analysis of the UNOS database. J Am Soc Nephrol 2003; 14(1):208–213.
21. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. Transplantation 2001; 71(1):82– 90.
22. Reddy KS, Stablein D, Taranto S, et al. Long-term survival following simultaneous kidney-pancreas transplantation versus kidney transplantation alone in patients with type 1 diabetes mellitus and renal failure. Am J Kidney Dis 2003; 41(2):464– 470.
23. Robertson RP, Davis C, Larsen J, Stratta R, Sutherland DE. Pancreas and islet transplantation in type 1 diabetes. Diabetes Care 2006; 29(4):935.
24. Fritsche A, Stefan N, Haring H, Gerich J, Stumvoll M. Avoidance of hypoglycemia restores hypoglycemia awareness by increasing beta-adrenergic sensitivity in type 1 diabetes. Ann Intern Med 2001; 134(9 Pt 1):729–736.
25. Diamanatopoulos S, Allende G, Martin-Pagola A, et al. Recurrence of Type 1 Diabetes (T1DR) after simultaneous pancreas–kidney (SPK) transplantation is associated with islet cell autoantibody conversion[abstract]. Acta Diabetol. 2007; 44(Suppl 1):S12.
26. Allene G, Diamanatopoulos S, Ferreira J, Burke GW, Pugliese A. Retrospective assessment of islet cell auto-antobidies in pancreas-organ donors [abstract]. Acta Diabetol. 2007; 44(Suppl 1): S2.
27. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343(4):230–238.
28. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, Macdonald AS. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355(9201): 376–377.
29. Couzin J. Diabetes. Islet transplants face test of time. Science 2004; 306(5693):34– 37.
30. Rother KI, Harlan DM. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest 2004; 114(7):877–883.
31. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54(7):2060–2069.
32. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355(13):1318–1330.
33. Koh A, Rudnisky C, Tennant M, et al. Stabilization of diabetic retinopathy following clinical islet transplantation [abstract]. Acta Diabetol. 2007; 44(Suppl 1): S28.
34. Bhargava R, Senior PA, Ackerman TE, et al. Prevalence of hepatic steatosis after islet transplantation and its relation to graft function. Diabetes 2004; 53(5):1311–1317.
35. Hirshberg B, Mog S, Patterson N, Leconte J, Harlan DM. Histopathological study of intrahepatic islets transplanted in the nonhuman primate model using edmonton protocol immunosuppression. J Clin Endocrinol Metab 2002; 87(12):5424–5429.
36. Senior PA, Zeman M, Paty BW, Ryan EA, Shapiro AM. Changes in renal function after clinical islet transplantation: Four-year observational study. Am J Transplant 2007; 7(1):91–98.
37. Mohanakumar T, Narayanan K, Desai N, et al. A significant role for histocompatibility in human islet transplantation. Transplantation 2006; 82(2):180–187.
38. Campbell PM, Senior PA, Salam A, et al. High risk of sensitization after failed islet transplantation. Am J Transplant 2007; 7(10):2311–2317.
39. Keymeulen B, Gillard P, Mathieu C, et al. Correlation between beta cell mass and glycemic control in type 1 diabetic recipients of islet cell graft. Proc Natl Acad Sci USA 2006; 103(46):17444–17449.
40. Korsgren O, Nilsson B, Berne C, et al. Current status of clinical islet transplantation. Transplantation 2005; 79(10):1289–1293.
41. Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: Continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51(7):2148– 2157.
42. Korsgren O, Lundgren T, Felldin M, et al. Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia 2008; 51(2):227–232.
43. Bennet W, Groth CG, Larsson R, Nilsson B, Korsgren O. Isolated human islets trigger an instant blood mediated inflammatory reaction: Implications for intraportal islet transplantation as a treatment for patients with type 1 diabetes. Ups J Med Sci 2000; 105(2):125–133.
44. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360(9350):2039–2045.
45. Cabric S, Sanchez J, Lundgren T, et al. Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. Diabetes 2007; 56(8):2008–2015.
46. Calafiore R, Basta G, Luca G, et al. Standard technical procedures for microencap-sulation of human islets for graft into nonimmunosuppressed patients with type 1 diabetes mellitus. Transplant Proc 2006; 38(4):1156–1157.
47. Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007; 83(1):24–28.
48. Gale EA. Can we change the course of beta-cell destruction in type 1 diabetes? N Engl J Med 2002; 346(22):1740–1742.